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Background: In previous studies, psoriasis has been reported 
to be associated with metabolic syndrome. Objective: The 
purpose of this study was to evaluate risk factors for 
metabolic syndrome in psoriasis patients and to compare the 
prevalence of metabolic syndrome in psoriasis and control 
groups. Methods: All patients (n=490) and controls (n=682) 
were investigated for cardiovascular risk factors, including 
central obesity, hypertension, fasting plasma glucose levels, 
and blood levels of triglycerides and high-density lipoprotein 
(HDL). Results: We found no statistical association between 
psoriasis and the prevalence of metabolic syndrome when 
controlling for age and gender. Among individual com-
ponents of metabolic syndrome, only increased triglyceride 
levels was significantly prevalent in patients psoriasis. The 
incidence of other factors such as central obesity, hyper-
tension, fasting plasma glucose and HDL in the psoriasis 
group were similar to or lower than those in the control 
group. Although psoriasis patients with metabolic syndrome 
had severe and large plaque-type psoriasis, the association of 
metabolic syndrome with the severity or clinical subtype of 
psoriasis was not significant after adjusting for age and 
gender. Conclusion: Our results suggest that there is no close 
correlation between psoriasis and metabolic syndrome in 
Korean patients. (Ann Dermatol 24(1) 11∼15, 2012)
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INTRODUCTION
Recent studies have reported that psoriasis is associated 
with metabolic disorders, including obesity, dyslipidemia, 
and diabetes
1-3. Moreover, psoriasis has been shown to be 
an independent risk factor for myocardial infarction, 
particularly in young patients, and severe psoriasis has 
been shown to be associated with increased mortality in 
patients with cardiovascular disease
4-6.
Metabolic syndrome, which is called insulin resistance 
syndrome or syndrome X, is a combination of cardiovascular 
risk factors, including central obesity, hypertension, glucose 
intolerance, and dyslipidemia
7. This comprehensive concept 
of metabolic syndrome is of clinical significance because 
it can be a strong predictor of cardiovascular diseases, 
diabetes, and stroke
8,9. 
Although the number of reports about the relationship of 
psoriasis with metabolic syndrome has been increasing in 
western countries, such reports are rare in Korea. 
Therefore, we investigated the association of psoriasis 
with cardiovascular risk factors and the prevalence of 
metabolic syndrome in Korean patients with psoriasis.
MATERIALS AND METHODS
Patients and controls
The subjects of this study were 490 patients with psoriasis 
who visited the Department of Dermatology at the Pusan 
National University Hospital between 1999 and 2009. GW Kim, et al
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Only patients over 18 years of age were included in the 
study. The severity of psoriasis was assessed using Molin’s 
classification
10, which is based on the body surface area 
affected by psoriasis: mild, ＜5% of the surface area; 
moderate, 5∼30%; and severe, ＞30%. Clinical subtypes 
of psoriasis were classified on the basis of the suggestion 
of Youn and Jo
11. While nummular-type and large plaque- 
type psoriasis were included in this study, other types 
such as guttate-type, erythrodermic, and generalized 
pustular psoriasis, and palmoplantar pustulosis were not. 
The following criteria should be satisfied for the classifi-
cation of nummular type: chronic course in older patients, 
larger cutaneous lesions (typically 1∼2 cm), and absence 
of pre-existing staphylococcal infections.
The exclusion criteria were as follows: patients who had 
secondary hyperlipidemia (hypothyroidism, nephrotic synd-
rome, chronic renal insufficiency, obstructive liver disease, 
and connective tissue disease); patients using medications 
affecting carbohydrate and lipid metabolism (beta blockers, 
thiazides, corticosteroids, and lipid-lowering agents); patients 
with infectious diseases; and patients who were pregnant 
and breastfeeding. Controls were selected from the Health 
Promotion Center of the Pusan National University Hos-
pital from May to July 2009. They had no underlying 
hepatic and renal disorders or infectious diseases. 
Data collection 
1) Investigation of cardiovascular risk factors
The charts of all patients were reviewed to identify the 
presence of chronic internal diseases, including diabetes 
mellitus and hypertension. Triglyceride and high-density 
lipoprotein (HDL)-cholesterol levels were investigated from 
the initial blood test. In addition, clinical data, including 
weight, height, body mass index (BMI), and waist circum-
ference, were collected using telephone surveys. Further-
more, a recent history of diabetes and hypertension and 
data regarding blood glucose levels and blood pressure 
measured in the most recent test were collected, again 
during the telephone surveys. On the basis of this investi-
gation, we assessed the presence of obesity, hypertension, 
and high fasting plasma glucose levels and blood levels of 
triglycerides and HDL-cholesterol.
2) Definition of metabolic syndrome
The criteria for diagnosing metabolic syndrome were 
obtained from the National Cholesterol Education 
Program’s Adult Panel III, and visceral obesity was defined 
by substituting it with BMI or the standard waist 
circumference in the Asia-Pacific Region. Diagnosis was 
confirmed when 3 or more of the following criteria were 
satisfied: central obesity (BMI ＞30 kg/m
2 or waist 
circumference  ≥36 inch for men and ≥32 inch for 
women), hypertension (≥130/85 mmHg), high fasting 
plasma glucose (≥110 mg/dl), increased triglycerides (≥
150 mg/dl), and decreased HDL (＜40 mg/dl for men and 
＜50 mg/dl for women).
Comparison of cardiovascular risk factors and metabolic 
syndrome 
1) Psoriasis group vs. control group 
After controlling for confounding factors such as age and 
gender, we analyzed and compared the prevalence of 
cardiovascular risk factors and metabolic syndrome 
between the psoriasis and control groups.
2) Psoriasis patients with metabolic syndrome vs. 
psoriasis patients without metabolic syndrome 
We compared the age, gender, clinical subtypes of 
psoriasis, and severity of psoriasis between these 2 groups.
Statistical analysis
Statistical comparison of the prevalence of metabolic 
syndrome in the psoriasis and control groups were 
performed using analysis of covariance (ANCOVA) for 
continuous variables and a chi-square test for categorical 
variables. We performed ANCOVA to control for the 
effects of age and gender in patients with metabolic 
syndrome. ANCOVA tests whether certain factors have an 
effect on the outcome variable after removing the variance 
that is accounted for by the quantitative predictors. We 
included age and gender as covariates to increase the 
statistical power of the analyses conducted in this study. 
All p-values were two-sided, and p＜0.05 was considered 
statistically significant.
RESULTS
Comparison of cardiovascular risk factors and metabolic 
syndrome: psoriasis group vs. control group
The prevalence of metabolic syndrome between the 
psoriasis and control groups, after controlling for age and 
gender, was not significantly different (p=0.200). In addition, 
intergroup differences in the incidence of hypertension 
and glucose intolerance and HDL levels were absent (p＞
0.05). The triglyceride levels in the psoriasis group were 
higher than those in the control group (p＜0.001) (Table 1).Analysis of Cardiovascular Risk Factors and Metabolic Syndrome in Korean Patients with Psoriasis
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Table 2. Comparisons of clinical features according to the presence of metabolic syndrome in psoriasis patients
Variable Without metabolic
syndrome 
With metabolic
syndrome  Ratio (with/without)  p-value
  Age (yr)  39.5±16.0  53.3±16.4  <0.001
  Sex 450 40   0.956 
    Male  268 (59.6) 24 (60.0) 24/268 (9.0)
    Female  182 (40.4)  16 (40.0)  16/182 (8.8) 
  Type 341 33   0.008 
    Nummular 266 (78.0) 19 (57.6) 19/266 (7.1)
    Large plaque   75 (22.0)  14 (42.4)    14/75 (18.7) 
  Severity 341 33   0.048 
    Mild 269 (78.9) 22 (66.7) 22/269 (8.2)
    Moderate  49 (14.4) 10 (30.3)   10/49 (20.4)
    Severe  23 (6.7)  1 (3.0)    1/23 (4.3) 
Values are presented as mean±standard deviation or number (%).
Table 1. Cardiovascular risk factors and metabolic syndrome in
the psoriasis and control groups (adjusting for age and gender,
%)
Variable Psoriasis 
(n=490)
Control
(n=682) F value p-value
Central obesity 28.0 40.8 17.3 ＜0.001
Hypertension 14.1 17.3 1.9 0.169
Glucose intolerance  9.6 7.0 2.3 0.132
Increased TG  42.7 26.2 28.2 ＜0.001
Decreased HDL 24.7 22.7 0.5 0.483
Metabolic syndrome  10.3 12.8 1.6 0.200
TG: triglyceride, HDL: high density lipoprotein.
Comparison of clinical features between psoriasis 
patients with metabolic syndrome and those without 
metabolic syndrome
Among the 490 psoriasis patients, 40 had metabolic 
syndrome and 450 had no metabolic syndrome. 
1) Age and gender
Psoriasis patients with metabolic syndrome were older 
than those without metabolic syndrome (53.3 years vs. 
39.5 years; p＜0.001). However, there was no significant 
difference in gender (p=0.956).
2) Clinical subtype (plaque type vs. nummular type) 
and severity
In patients with nummular-type psoriasis, the ratio between 
the presence (n=19) and absence (n=266) of metabolic 
syndrome was 7.1% (n=19/266). However, in patients 
with large plaque-type psoriasis, the ratio between the 
presence (n=14) and absence (n=75) of metabolic 
syndrome was 18.7% (n=14/75) (Table 2).
In the assessment of severity, the ratio between the 
presence and absence of metabolic syndrome was highest 
in the moderate psoriasis group (20.4%, n=10/49) (Table 
2). However, there was no significant difference in the 
prevalence of metabolic syndrome according to the 
clinical subtype and severity after controlling for age and 
gender (p＞0.05).
DISCUSSION
Psoriasis is a chronic inflammatory skin disease, and 
recent reports have increasingly shown the association 
between psoriasis and cardiovascular disease
6. In addition, 
epidemiological studies in the English language literature 
have established the direct relationship between psoriasis 
and metabolic syndrome
12,13. However, the relationship 
between cardiovascular risk factors and metabolic synd-
rome has not been sufficiently reported in the Korean 
literature. 
Therefore, we conducted a study on metabolic syndrome 
and cardiovascular risk factors in patients with psoriasis. 
Our study yielded the following results. First, the pre-
valence of metabolic syndrome was 10.3% in the psor-
iasis group (Table 1). Second, our statistical analysis did 
not show any significant difference in the prevalence of 
metabolic syndrome between the psoriasis and control 
groups after controlling for age and gender (p=0.200) 
(Table 1). Finally, the triglyceride level was higher in the 
psoriasis group (42.7%) than in the control group (26.2%, 
p＜0.001) (Table 1). 
There has been a rapid increase in the number of reports 
that link psoriasis to cardiovascular disease; however, 
there have also been some controversies on the relation-
ship between psoriasis and cardiovascular risk, parti-
cularly in patients with metabolic syndrome. In addition, 
only a few studies have investigated the direct relationship GW Kim, et al
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between metabolic syndrome and psoriasis
1,4,6,14-16. Although 
Gisondi et al.
12 reported that the prevalence of metabolic 
syndrome was higher in psoriasis patients (30.1%) than in 
patients with general dermatological conditions (20.6%), 
the prevalence of hypertriglyceridemia and abdominal 
obesity-individual components of the metabolic syndrome- 
was significantly greater in patients with psoriasis than in 
controls. In addition, Sommer et al.
13  observed a high 
prevalence of metabolic syndrome among patients (4.3%) 
with psoriasis than in controls (1.1%). However, the 
prevalence of metabolic syndrome in both patients (4.3%) 
and controls (1.1%) was very low, and the risk of 
metabolic syndrome was high only in patients with severe 
psoriasis.
This observation suggests that the occurrence of cardio-
vascular complications may be restricted to the severe 
form of psoriasis; however, this finding has not yet been 
confirmed. Recently, Wakkee et al.
17 conducted a large 
population-based Dutch cohort study and provided 
additional evidence suggesting that psoriasis or severe 
psoriasis may not be a relevant risk factor for myocardial 
infarction. In addition, genetic and racial differences may 
influence the prevalence of metabolic syndrome. According 
to Chen et al.
18, central obesity, hypertension, and glucose 
intolerance were more prevalent in Asian patients with 
psoriasis than in controls. However, the incidence of 
metabolic syndrome among psoriasis patients (14.1%) was 
lower than among controls (16.3%). 
The National Health Nutrition Examination Survey in 
Korea analyzed the prevalence of metabolic syndrome in 
1998 and 2001, and reported that 22.5% and 24.1% of 
Korean adults, respectively, had metabolic syndrome
19. 
The prevalence of metabolic syndrome was lower in our 
psoriasis group (10.3%) than in the groups of the above- 
mentioned survey and the groups mentioned in a recent 
study by Lym et al.
20 (20∼29 years [3.8%]; 30∼39 years 
[13.9%]; 40∼49 years [14.8%]; 50∼59 years [24.2%]; 60
∼69 years [27.1%]).
Our results showed that metabolic syndrome was not 
associated with psoriasis, but our study had several 
limitations. First, there is a possibility that young patients 
and those with early disease have been over-polled 
because this study was aimed at new patients visiting the 
outpatient clinic. Second, this study was a retrospective 
study and it might not reflect accurate results. In principle, 
strict numerical measurements had to be obtained to 
evaluate the risk factors of metabolic syndrome. However, 
this study used medical records and telephone surveys to 
investigate risk factors, and this may have introduced a 
bias. Psoriasis has a prolonged disease course, and a 
difference in the prevalence of metabolic syndrome may 
exist between early manifestation and chronic disease 
stages. Moreover, questions such as whether psoriasis 
predisposes the patient to metabolic syndrome and 
whether metabolic disorders can lead to psoriasis have 
remained unanswered
16. In this study, the investigation 
involved telephone surveys conducted over a follow-up 
period of up to 10 years and a comprehensive review of 
medical histories. This may have helped overcome the 
limitations of a cross-sectional study. Assuming a relation-
ship between psoriasis and metabolic syndrome, our 
findings may suggest that the onset of psoriasis leads to 
the development of metabolic syndrome.
Remarkably, our results showed higher levels of trigly-
cerides in the psoriasis group than in the control group 
(Table 2). In a cross-sectional study, which compared 
psoriasis patients with controls, 16,851 psoriasis patients 
in Israel showed increased total cholesterol and trigly-
cerides, decreased HDL, and no alteration in low-density 
lipoprotein (LDL)
21. Another cross-sectional study conducted 
in Iran showed that, compared to controls, psoriasis 
patients have significantly higher levels of triglycerides, 
total cholesterol, LDL, and very low-density lipoprotein, 
but no alteration in HDL
22. Therefore, we think that 
careful attention must be paid to dyslipidemia, particularly 
the triglyceride levels, in psoriasis patients. 
In addition, our study produced 3 meaningful results by 
comparing the two groups on the basis of the presence or 
absence of metabolic syndrome. First, psoriasis patients 
with metabolic syndrome (53.3 years) were significantly 
older than those without metabolic syndrome (39.5 years) 
(p＜0.001). Second, plaque-type psoriasis was much more 
common in patients with metabolic syndrome than in 
those without metabolic syndrome. Finally, patients with 
metabolic syndrome had more severe psoriasis than those 
without metabolic syndrome, as estimated on the basis of 
the body surface area (p=0.048) (Table 2).
This large-scale, long-term study investigated cardiovascular 
risk factors in Korean patients. Although we did not find 
any significant differences in the prevalence of metabolic 
syndrome between psoriasis patients and controls, the 
results of our study suggest that patient age and severity of 
psoriasis are predisposing factors for metabolic syndrome. 
Thus, special care must be taken in the case of elderly 
patients with plaque-type psoriasis. In addition, trigly-
ceride levels showed significant correlations with psoriasis 
in this study, and hence plasma lipid profiling should be 
routinely conducted. 
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